Development and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor.

Skwarska, Anna; Calder, Ewen D D; Sneddon, Deborah; Bolland, Hannah; Odyniec, Maria L; Mistry, Ishna N; Martin, Jennifer; Folkes, Lisa K; Conway, Stuart J; Hammond, Ester M

Skwarska, Anna; Calder, Ewen D D; Sneddon, Deborah; Bolland, Hannah; Odyniec, Maria L; Mistry, Ishna N; Martin, Jennifer; Folkes, Lisa K; Conway, Stuart J; Hammond, Ester M.

Afiliação

Skwarska A; Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK.
Calder EDD; Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford OX1 3TA, UK.
Sneddon D; Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford OX1 3TA, UK.
Bolland H; Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK.
Odyniec ML; Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford OX1 3TA, UK.
Mistry IN; Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK.
Martin J; Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK.
Folkes LK; Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK.
Conway SJ; Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford OX1 3TA, UK. Electronic address: stuart.conway@chem.ox.ac.uk.
Hammond EM; Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK. Electronic address: ester.hammond@oncology.ox.ac.uk.

Cell Chem Biol ; 28(9): 1258-1270.e13, 2021 09 16.

Article em En | MEDLINE | ID: mdl-33910023

Assuntos

Antineoplásicos/farmacologia; Desenvolvimento de Medicamentos; Inibidores de Histona Desacetilases/farmacologia; Histona Desacetilases/metabolismo; Hipóxia/tratamento farmacológico; Panobinostat/farmacologia; Animais; Antineoplásicos/síntese química; Antineoplásicos/química; Apoptose/efeitos dos fármacos; Proliferação de Células/efeitos dos fármacos; Sobrevivência Celular/efeitos dos fármacos; Ensaios de Seleção de Medicamentos Antitumorais; Feminino; Inibidores de Histona Desacetilases/síntese química; Inibidores de Histona Desacetilases/química; Hipóxia/metabolismo; Masculino; Camundongos; Camundongos Nus; Estrutura Molecular; Neoplasias Experimentais/tratamento farmacológico; Neoplasias Experimentais/metabolismo; Neoplasias Experimentais/patologia; Panobinostat/síntese química; Panobinostat/química; Células Tumorais Cultivadas

Palavras-chave

HAP; HDAC; KDAC; hypoxia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Histona Desacetilases / Desenvolvimento de Medicamentos / Panobinostat / Histona Desacetilases / Hipóxia / Antineoplásicos Limite: Animals Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google